Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mauriac

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 14, 2011
Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-upA Avril, G Le Bouëdec, G Lorimier, et al.
Breast Cancer Research and Treatment|June 9, 2000
EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancerA Hamilton, J A Roy, L Beex, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of CancerA Hamilton, L Biganzoli, R Coleman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyW Eiermann, S Paepke, J Appfelstaedt, et al.
Gynecologie, Obstetrique & Fertilite|April 22, 2008
[Male breast cancer: a review of 52 cases collected at the Institute Bergonié (Bordeaux, France) from 1980 to 2004]C Tunon de Lara, G Goudy, G Macgrogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2001
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trialM J Ellis, A Coop, B Singh, et al.
British Journal of Cancer|August 14, 2003
DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancerG MacGrogan, P Rudolph, I de Mascarel Id, et al.
Journal of the National Cancer Institute|June 8, 2000
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized studyJ G Klijn, L V Beex, L Mauriac, et al.
British Journal of Cancer|October 20, 2011
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancerE Brain, C Levy, D Serin, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2000
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experienceJ Bonneterre, M Spielman, J P Guastalla, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 14, 2011
Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-upA Avril, G Le Bouëdec, G Lorimier, et al.
Breast Cancer Research and Treatment|June 9, 2000
EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancerA Hamilton, J A Roy, L Beex, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of CancerA Hamilton, L Biganzoli, R Coleman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyW Eiermann, S Paepke, J Appfelstaedt, et al.
Gynecologie, Obstetrique & Fertilite|April 22, 2008
[Male breast cancer: a review of 52 cases collected at the Institute Bergonié (Bordeaux, France) from 1980 to 2004]C Tunon de Lara, G Goudy, G Macgrogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2001
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trialM J Ellis, A Coop, B Singh, et al.
British Journal of Cancer|August 14, 2003
DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancerG MacGrogan, P Rudolph, I de Mascarel Id, et al.
Journal of the National Cancer Institute|June 8, 2000
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized studyJ G Klijn, L V Beex, L Mauriac, et al.
British Journal of Cancer|October 20, 2011
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancerE Brain, C Levy, D Serin, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2000
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experienceJ Bonneterre, M Spielman, J P Guastalla, et al.
Pageof 9